Who We Are

Lysine Biotech is a Chennai based start-up biotech company established in the year 2018. Lysine Biotech Private Limited Resident startups at Atal Incubation Centre – CCMB, Hyderabad.

We are currently involved in developing therapeutics against diabetics and acutely decompensated congestive heart failure with dyspnea at rest. Our aim is to provide affordable, safe and effective drugs/vaccine for diseases with global prevalence. We have i)Development of anti-GeneX antibody-based CAR-T cells for treatment of cancer, ii) Development of tri-specific anti-RBD SPIKE antiviral-based Ankyrin Repeats for treatment of SARS-CoV-2 and Development of 1st fourteen-in-One, 2nd fourteen-in-One and 3rd fifteen-in-One anti-proteinX antiviral-based Targeted Protein Degradation therapies designed for treatment of Pancoronavirus and iii) PROTAC has gained tremendous momentum for its promise to discover and develop new drugs in pipeline.

Lysine Biotech is committed to product development and manufacturing of drugs, biomarker and vaccines for several disease, Infectious diseases and biological molecules are produced from living organisms and range from DNA and protein through in-silico and wet lab technologies, which are useful for the medicinal and industrial applications.

Learn More About Us

Our Features

Our wild-type library non coding frame endless RNA (ncfeRNA)1,— a new class of programmable medicines capable of expressing therapeutic proteins, Membrane Proteins, Peptides, Antibodies, Vaccine inside the body.

i) ncfeRNA engineered to translate programmed frame genetic non code and express proteins
ii)Stability functions and long lasting.
iii).Uses non-coding frame regions to control expression, stability, targeting and more.

Reference

1.P. Anandagopu, V.Jayaraj, R.suganya and E.Rajasekaran (2008). Role of Thymine in Protein Coding Frames of mRNA Sequences. Bioinformation. 2, 304-307.

Learn More About Technology